Back to Search Start Over

Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7).

Authors :
Bernasconi R
Thriene K
Romero-Fernández E
Gretzmeier C
Kühl T
Maler M
Nauroy P
Kleiser S
Rühl-Muth AC
Stumpe M
Kiritsi D
Martin SF
Hinz B
Bruckner-Tuderman L
Dengjel J
Nyström A
Source :
EMBO molecular medicine [EMBO Mol Med] 2021 Oct 07; Vol. 13 (10), pp. e14392. Date of Electronic Publication: 2021 Aug 30.
Publication Year :
2021

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB), a genetic skin blistering disease, is a paradigmatic condition of tissue fragility-driven multi-organ fibrosis. Here, longitudinal analyses of the tissue proteome through the course of naturally developing disease in RDEB mice revealed that increased pro-inflammatory immunity associates with fibrosis evolution. Mechanistically, this fibrosis is a consequence of altered extracellular matrix organization rather than that of increased abundance of major structural proteins. In a humanized system of disease progression, we targeted inflammatory cell fibroblast communication with Ang-(1-7)-an anti-inflammatory heptapeptide of the renin-angiotensin system, which reduced the fibrosis-evoking aptitude of RDEB cells. In vivo, systemic administration of Ang-(1-7) efficiently attenuated progression of multi-organ fibrosis and increased survival of RDEB mice. Collectively, our study shows that selective down-modulation of pro-inflammatory immunity may mitigate injury-induced fibrosis. Furthermore, together with published data, our data highlight molecular diversity among fibrotic conditions. Both findings have direct implications for the design of therapies addressing skin fragility and fibrosis.<br /> (© 2021 The Authors. Published under the terms of the CC BY 4.0 license.)

Details

Language :
English
ISSN :
1757-4684
Volume :
13
Issue :
10
Database :
MEDLINE
Journal :
EMBO molecular medicine
Publication Type :
Academic Journal
Accession number :
34459121
Full Text :
https://doi.org/10.15252/emmm.202114392